BioSpace News Archive

Business

Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights

Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights.

May 16, 2022
·
14 min read
Business

TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for the first quarter ended March 31, 2022, and recent business progress.

May 16, 2022
·
8 min read
Business

Axion BioSystems Welcomes Biotech Industry Leader Kevin Gould as New CEO

Axion BioSystems, a leading life science tools company focused on advanced live-cell assay platforms, announces that Kevin Gould has been appointed the company’s Chief Executive Officer, effective immediately.

May 16, 2022
·
3 min read
Human Microbiome Market Growth Rate of 31.1 % over the Forecast years (2022-2029) – Global Industry Analysis

The corporate intelligence reports predict that the global human microbiome market will record an astounding compound annual growth rate of 31.1 % over the forecast years i.e. 2023 to 2029.

May 16, 2022
·
9 min read
Drug Development

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Angion Biomedica Corp. announced U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis and clearance to begin a Phase 1b study of ANG-3070 in patients with IPF.

May 16, 2022
·
6 min read
Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

ValnevaSE announced that it has received a notice from the European Commission of intent to terminate the advance purchase agreement for Valneva’s inactivated whole-virus COVID-19 vaccine candidate VLA2001.

May 16, 2022
·
6 min read